fda approval

  1. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Read more »
  2. New study supports FDA's decision to approve Copiktra (duvelisib)

    woman smiling sunny

    Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

    Read more »
  3. Truxima (rituximab) gains FDA approval as the first biosimilar for Non-Hodgkin's Lymphoma

    A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

    approved stamp with stars

    Read more »